
Biocept Appoints Financial Executive Quyen Dao-Haddock to its Board of Directors
“Quyen’s extensive financial experience leading accounting and finance departments, and overseeing technical accounting, budgeting and forecasting, financial modeling, cash management and
“It’s an exciting time to join the Biocept Board as the Company directs its resources toward providing valuable information to improve clinical outcomes for patients with cancer and central nervous system involvement, who oftentimes have extremely poor prognoses,” said Ms. Dao-Haddock. “I’m delighted to utilize my skills and expertise to support the advancement of CNSide and the Company’s diagnostic programs.”
Ms. Dao-Haddock serves as controller of
Ms. Dao-Haddock serves on the Audit &
About
Forward-Looking Statements Disclaimer
This press release contains forward-looking statements that are based upon current expectations or beliefs, as well as a number of assumptions about future events. Although we believe that the expectations reflected in the forward-looking statements and the assumptions upon which they are based are reasonable, we can give no assurance that such expectations and assumptions will prove to be correct. Forward-looking statements are generally identifiable by the use of words like "may," "will," "should," "could," "expect," "anticipate," "estimate," "believe," "intend," “goal,” or "project," or the negative of these words or other variations on these words or comparable terminology. To the extent that statements in this press release are not strictly historical, including, without limitation, statements regarding our ability to establish CNSide as the new standard-of-care diagnostic test for patients with metastatic cancer that has spread to the central nervous systems, and the ability of our products, including CNSide, to provide physicians with clinically actionable information for treating and monitoring patients diagnosed with a variety of cancers, such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The reader is cautioned not to put undue reliance on these forward-looking statements, as these statements are subject to numerous risks and uncertainties, including risks and uncertainties associated with the ability of our products to compete successfully with competitive products or treatments; our ability to obtain and maintain adequate reimbursement for our products; and the risk that our products and services may not perform as expected. These and other factors are described in greater detail under the "Risk Factors" heading of Biocept’s Quarterly Report on Form 10-Q for the quarter ended
View source version on businesswire.com: https://www.businesswire.com/news/home/20221118005082/en/
Investor and Media Contact:
Jcain@lhai.com, 310-691-7100
Source: